Clinical Trial

OH2 Administered by Intratumoral Injection

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will be a Phase 1, multi-center, open-label, dose escalation followed by the recommended phase 2 dose (RP2D) expansion study to characterize safety, tolerability, biodistribution, virus shedding and preliminary efficacy of intratumoral injection of OH2 in patients with locally advanced/metastatic solid tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-07-12; most recent amendment 2024-12-23.
Trial Details
NCT Number NCT05954091
Lead Sponsor Binhui Biopharmaceutical Co., Ltd.
Conditions Solid Tumor
Enrollment 29 participants
Start Date 2025-09-01
Primary Completion 2027-07-01 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-27